TrialNature medicine2025

Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial.

Raajit K Rampal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.